Author’s response to reviews

Title: microRNA-21 promotes breast cancer proliferation and metastasis by targeting LZTFL1

Authors:
Hui Wang (027whwh@sina.com)
Zheqiong Tan (tanzheqiong@csu.edu.cn)
Hui Hu (476037893@qq.com)
Hongzhou Liu (azura@whu.edu.cn)
Tangwei Wu (wutangweitw@sina.cn)
Chao Zhen (479332484@qq.com)
Xiuling Wang (xiuling19890430@163.com)
Zhenzhao Luo (lzzbvy@163.com)
Jing Wang (wangjing1219_2007@163.com)
Shuiyi Liu (13657299903@139.com)
Zhongxin Lu (lzx71@yahoo.com)
Jiancheng Tu (jianchengtu@whu.edu.cn)

Version: 4 Date: 14 Jul 2019

Author’s response to reviews:

Dear Editors,

Thank you very much for providing us an opportunity to revise the manuscript. We appreciate reviewers for their positive comments and constructive critiques. We revised the manuscript and listed our point-to-point response to reviewers’ comments in the rebuttal letter.
We would like to submit this revised manuscript to BMC Cancer, and hope it is acceptable for publication. If you have any question, please do not hesitate to contact me at the address below. Thanks again and I am looking forward to hearing from you soon.

Sincerely,

Jiancheng Tu, Prof.

Department & Program of clinical laboratory Medicine, center for gene Diagnosis, Zhongnan hospital of Wuhan University, 169 Donghu road, Wuhan 430071, People’s republic of china

Tel +86 27 6781 2989   Fax +86 27 6781 3233

Email : jianchengtu@whu.edu.cn

Point-by-point Response:

Editor Comments:

1 - Please remove any files from the file inventory that you do not wish to see published.

Answer: Thank you for your comment. We have removed the files from the file inventory that we do not wish to see published.

2 - If human cell lines are used, authors are strongly encouraged to include the following information in their manuscript:

• The source of the cell line, including when and from where it was obtained
• Whether the cell line has recently been authenticated and by what method
• Whether the cell line has recently been tested for mycoplasma contamination

Further information is available from the International Cell Line Authentication Committee (ICLAC). We recommend that authors check the NCBI database for misidentification and contamination of human cell lines. Please include the sources of all cell lines and their catalogue numbers.
Answer: Thank you for your advice. We obtained all the cell lines from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) in 2017 and we included the information and catalogue numbers in Methods. Short tandem repeat genotyping and mycoplasma contamination were conducted by the Cell Bank of the Chinese Academy of Sciences when we obtained the cell lines.

3 - Please confirm whether any of the cell lines required ethics approval for their use and include a statement in the Ethics approval and consent to participate section in the Declarations.

Answer: We did not include any cell lines required ethics approval for their use.

4 - Please include an Availability of Data and Materials statement in the Declarations and ensure it reflects accurately one of the formats indicated in our submission guidelines for the raw data: https://www.biomedcentral.com/getpublished/editorial-policies#availability+of+data+and+materials

Answer: All data generated or analyzed during this study are included in this published article.

5 - At this stage, please upload your proofread manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethrough or text in different colours. All relevant tables and figures should also be clean versions. Figures (and additional files) should remain uploaded as separate files. Should you wish to respond to these revision requests, please include the information in the designated input box only.

Answer: We uploaded our proofread manuscript as a single, final, clean version. Tables and figures were uploaded as clean versions and separate files.